RxDoctor Payments Data

Carlos Obregon, DO

Pulmonary Disease · Sewell, NJNPI 1093785487

Payments from drug & device makers

$11,934in general payments, 2019–2025

Across 753 payments — averaging $15.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$1K
  • Sanofi$992
  • Actelion Pharmaceuticals US, Inc.$980
  • Regeneron Healthcare Solutions, Inc.$871
  • Intuitive Surgical$868
  • plus $5K from 35 others

What the payments were for

  • Travel & lodging$8037%
  • Food & beverage$10,92392%
  • Education$2082%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,934 in reported general payments places this provider in the 80th percentile of 472 pulmonary disease providers in New Jersey.

See all pulmonary disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$361,817
Medicare patients
822
Services billed
3,328

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan77$1,006,471
UptraviSelexipag21$479,156
AdempasRiociguat29$403,551
XolairOmalizumab43$311,729
LetairisAmbrisentan18$239,034
Arnuity ElliptaFluticasone Furoate316$122,385
Breo ElliptaFluticasone/Vilanterol196$102,666
Ambrisentan31$91,155
FasenraBenralizumab13$73,800
Dupixent PenDupilumab18$65,783
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$57,084
EliquisApixaban84$56,277
NucalaMepolizumab16$56,053
Orenitram ErTreprostinil Diolamine21$30,516
Qvar RedihalerBeclomethasone Dipropionate57$28,896

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$980$1,485,62698 claims
BayerAdempas$253$403,55129 claims
GSKArnuity Ellipta, Breo Ellipta, Trelegy Ellipta, Nucala, Anoro Ellipta$1,345$358,241615 claims
GileadLetairis$13$239,03418 claims
AstraZenecaFasenra, Breztri Aerosphere, Pulmicort Flexhaler, Symbicort$2,347$119,150100 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$99$28,89657 claims
MerckDulera, Asmanex$87$11,75132 claims
Covis Pharma GmbHAlvesco$91$6,26213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 472 pulmonary disease providers in New Jersey.

Other pulmonary disease in Sewell

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →